Figure 7.

The effect of plasma samples of type 2 diabetes (T2D) patients on the viability of MSCs was assayed by MTT analysis. A—MSCs was treated by 5% v/v plasma samples of healthy donors; B, C—MSCs was treated by 5% v/v plasma samples of T2D patients. Groups were divided by a cell viability threshold of 60%. Group B—MSCs viability above 60%, group C—MSCs viability ≤ 60% and attend by cell death ≥ 10%. Group survival was calculated compared with control cells incubated in a complete nutrient medium and taken as 100%. * p < 0.05, ** p < 0.01 compared with control.